Pharmaceutical giant Mylan announced on Monday that the company has settled with Genentech Inc. (a unit of Roche Holding AG), and F. Hoffmann-La Roche (ROG) over patents for Herceptin. Herceptin is Mylan’s brand name for trastuzumab which is used to treat certain HER2-positive breast cancers. The company currently markets its trastuzumab products in 14 emerging … Continue reading “What Does Mylan Settling Over Patents For Herceptin Mean For The Company Now?”
